ReviewDiscover oncology2025

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.

Ya Hwee Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.